Microenvironmental Regulation of Tumour Immunity and Response to Immunotherapy

Overview

Journal J Pathol

Specialty Pathology

Date 2021 Apr 13

PMID 33846997

Citations 11

Authors

Mark M Kockx

Mark McCleland

Hartmut Koeppen

Affiliations

Soon will be listed here.

Abstract

The confluence of immunology and oncology has led to a lot of uncertainty and questions about relevant biomarkers. Despite the complexity of the tumour microenvironment, most clinical studies have relied on a single-parameter immunohistochemical assay to prospectively select patients for checkpoint inhibitor therapy; the results of this strategy have been highly variable and often less than optimal. While great efforts have been made to identify additional or alternative biomarkers, pathologists, drug developers, and clinicians alike have faced technical, logistical, and regulatory challenges on how to implement them successfully. In this review, we will discuss these challenges; we will also highlight recent advances in dissecting the functional diversity of immune cell populations within the tumour microenvironment and their potential for improved, biomarker-driven therapeutic strategies. The dynamic nature and cellular diversity of the tumour microenvironment may challenge past models of a single biomarker predicting patient response and clinical outcome. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Citing Articles

Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer.

Elfving H, Yu H, Fessehatsion K, Brunnstrom H, Botling J, Gulyas M Cell Oncol (Dordr). 2025; .

PMID: 40029549 DOI: 10.1007/s13402-025-01052-x.

Inhibiting HnRNP L-mediated alternative splicing of EIF4G1 counteracts immune checkpoint blockade resistance in Castration-resistant prostate Cancer.

Cheng S, Chen Z, Zhang J, Wang J, Li Q, Zhou X Neoplasia. 2024; 60:101109.

PMID: 39724754 PMC: 11731738. DOI: 10.1016/j.neo.2024.101109.

Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.

Yue S, Zhang Y, Zhang W Curr Treat Options Oncol. 2024; 25(8):1089-1111.

PMID: 39066855 PMC: 11329538. DOI: 10.1007/s11864-024-01243-y.

CAFs orchestrates tumor immune microenvironment-A new target in cancer therapy?.

Zhang C, Fei Y, Wang H, Hu S, Liu C, Hu R Front Pharmacol. 2023; 14:1113378.

PMID: 37007004 PMC: 10064291. DOI: 10.3389/fphar.2023.1113378.

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer.

Peng Y, Li Z, Fu Y, Pan Y, Zeng Y, Liu J Front Oncol. 2023; 13:1011810.

PMID: 36761954 PMC: 9905802. DOI: 10.3389/fonc.2023.1011810.

References

Sow H, Ren J, Camps M, Ossendorp F, Ten Dijke P . Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. Cells. 2019; 8(4). PMC: 6523576. DOI: 10.3390/cells8040320. View

de Sousa E Melo F, Kurtova A, Harnoss J, Kljavin N, Hoeck J, Hung J . A distinct role for Lgr5 stem cells in primary and metastatic colon cancer. Nature. 2017; 543(7647):676-680. DOI: 10.1038/nature21713. View

Scheper W, Kelderman S, Fanchi L, Linnemann C, Bendle G, de Rooij M . Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2018; 25(1):89-94. DOI: 10.1038/s41591-018-0266-5. View

Feng S, Cheng X, Zhang L, Lu X, Chaudhary S, Teng R . Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers. Proc Natl Acad Sci U S A. 2018; 115(40):10094-10099. PMC: 6176562. DOI: 10.1073/pnas.1800695115. View

Gandara D, Paul S, Kowanetz M, Schleifman E, Zou W, Li Y . Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018; 24(9):1441-1448. DOI: 10.1038/s41591-018-0134-3. View

Ganesh K, Massague J . TGF-β Inhibition and Immunotherapy: Checkmate. Immunity. 2018; 48(4):626-628. PMC: 6347120. DOI: 10.1016/j.immuni.2018.03.037. View

Fares C, Van Allen E, Drake C, Allison J, Hu-Lieskovan S . Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. Am Soc Clin Oncol Educ Book. 2019; 39:147-164. DOI: 10.1200/EDBK_240837. View

Tirosh I, Izar B, Prakadan S, Wadsworth 2nd M, Treacy D, Trombetta J . Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016; 352(6282):189-96. PMC: 4944528. DOI: 10.1126/science.aad0501. View

Chen X, Yuan S, Duan J, Chen Y, Chen S, Wang Y . The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. Dis Markers. 2021; 2020:6717912. PMC: 7787798. DOI: 10.1155/2020/6717912. View

10.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

11.

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

12.

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

13.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

14.

Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R . Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018; 36(34):3353-3360. DOI: 10.1200/JCO.18.01148. View

15.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

16.

Gonzalez-Ericsson P, Stovgaard E, Sua L, Reisenbichler E, Kos Z, Carter J . The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020; 250(5):667-684. DOI: 10.1002/path.5406. View

17.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

18.

Kowanetz M, Zou W, Gettinger S, Koeppen H, Kockx M, Schmid P . Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci U S A. 2018; 115(43):E10119-E10126. PMC: 6205493. DOI: 10.1073/pnas.1802166115. View

19.

Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R . Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018; 175(4):998-1013.e20. PMC: 6641984. DOI: 10.1016/j.cell.2018.10.038. View

20.

van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit L, de Feijter J . Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020; 26(12):1839-1844. DOI: 10.1038/s41591-020-1085-z. View